Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
- Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer
- Acquisition would add?177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC)
- Endocyte offers radiopharmaceutical programs with significant sales potential
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Julie Masow Novartis Oncology Media Relations +1 862 778 7220 (direct) +1 862 579 8456 (mobile) julie.masow@novartis.com |